Approvals· September 5, 2026 · 29 min read
Topic
NCCN Guidelines
National Comprehensive Cancer Network guideline updates, Category 1 and 2A recommendations, and their role in prior authorization and appeals.
Approvals· September 4, 2026 · 36 min read
Lirafugratinib's Sept 27 PDUFA Does Not Rewrite Pemazyre PAs or Lytgobi CDx
By Ran Chen#PDUFA Date#FDA Approval#NDA Approval
Pricing & Access· May 30, 2026 · 11 min read
Datroway TNBC coverage guide: TROP2 ADC access and coding
By Ran Chen#ADC#Breast Cancer#Prior Authorization
Pipeline· May 27, 2026 · 7 min read
ASCO 2026 pipeline evidence preview for formulary and access teams
Pricing & Access· May 27, 2026 · 9 min read
Padcev plus Keytruda urothelial cancer access guide
Pricing & Access· May 27, 2026 · 9 min read
Trodelvy access guide for breast cancer coverage
By Ran Chen#Oncology#ADC#Prior Authorization
Pricing & Access· May 26, 2026 · 7 min read
Veppanu coverage guide for ER+/HER2- breast cancer
By Ran Chen#PROTAC#Breast Cancer#Companion Diagnostic